Quassinoid


Quassinoids are degraded triterpene lactones of the Simaroubaceae plant family grouped into C-18, C-19, C-20, C-22 and C-25 types. The prototypical member of the group, quassin, was first described in the 19th century from plants of the genus Quassia from which it gets its name. It was isolated in 1937 and its structure elucidated in 1961.
They are a biologically potent class of natural products, possessing antimalarial, antifeedant, insecticidal, anti-inflammatory, and anticancer properties. The quassinoid bruceantin reached two separate phase II clinical trials in 1982 and 1983. Although it was considered to be toxic to cells in the 1980s, after the 21st century, some pharmaceutical experts began to conduct research and development of lead drugs for Quassinoids. It clarified that it has excellent potential for pharmaceutical preparation, and launched research in 2020 Targeted approach, trying to develop inhibitors that target specific viruses and prevent the virus's own protein transcription.
Other quassinoids include: